EGFR and neoplasm: In conclusion, our findings suggest that anti-EGFR mAb plus chemotherapy may offer better tumor shrinkage than chemotherapy alone or combined with bevacizumab in patients with RAS wild-type mCRC regardless of tumor location, which may translate into consistent probabilities for undergoing secondary resection.